Development and Validation of the SCOPE-MM Score: A Pre-Apheresis Risk Model Predicting Response and Toxicity in RRMM Patients Receiving BCMA-Directed CAR-T Therapy

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03407-X

David M. Cordas dos Santos MD, Kai Rejeski MD, MHBA, Susan M. Geyer PhD, Katharine E. Dooley PhD, Tobias Tix MD, Florian Bassermann MD, Omar Castaneda Puglianini MD, Saurabh Chhabra MD, Patrick Costello, Ciara L. Freeman MD, PhD, Jan Frenking MD, Mahmoud Gaballa MD, Yun Li PhD, Omar Nadeem MD, Ricardo Parrondo MD, Oren Pasvolsky MD, Krina K. Patel MD, MSc, Sridevi Rajeeve MD, Masooma S. Rana MD, Surbhi Sidana MD, Yi Lin MD, PhD

引用次数: 0

查看原文本刊更多论文

SCOPE-MM评分的开发和验证：一种预测接受bcma定向CAR-T治疗的RRMM患者反应和毒性的采前风险模型

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.